9
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6588 |
Mitoxantrone
米托蒽醌,mitozantrone |
Topoisomerase; PKC | Chromatin/Epigenetic; Cytoskeletal Signaling; DNA Damage/DNA Repair |
Mitoxantrone (mitozantrone) 是一种拓扑异构酶 II (Topo II) 的抑制剂,一种蛋白激酶 C (PKC) 的抑制剂 (IC50=8.5 μM)。Mitoxantrone 具有抗肿瘤活性,可以治疗急性髓系白血病、肝细胞癌、乳腺癌等。 | |||
T0158 |
Mitoxantrone dihydrochloride
米托蒽醌二盐酸盐,盐酸米托蒽醌,Mitoxantrone 2HCl,Mitoxantrone hydrochloride,NSC-301739,mitozantrone dihydrochloride |
Topoisomerase; PKC | Chromatin/Epigenetic; Cytoskeletal Signaling; DNA Damage/DNA Repair |
Mitoxantrone dihydrochloride (NSC-301739) 是一种拓扑异构酶 II 的抑制剂;也可抑制蛋白激酶C (PKC),IC50值为8.5 μM。 | |||
T63997 |
Mitoxantrone diacetate
|
Others | Others |
Mitoxantrone diacetate 是拓扑异构酶II (topoisomerase II) 的有效抑制剂。Mitoxantrone diacetate 也能够抑制蛋白激酶 C (PKC) (IC50: 8.5 μM)。Mitoxantrone diacetate 能够诱导 B-慢性淋巴细胞白血病 (B-CLL) 细胞凋亡 (apoptosis)。Mitoxantrone diacetate 表现出抗肿瘤作用,也具有抗正痘病毒 (orthopoxvirus) 效果,能够作用于牛痘 (EC50: 0.25 μM) 和猴痘 (EC50: 0.8 μM)。 | |||
T83892 |
33-BCRP Inhibitor
33-Breast Cancer Resistance Protein Inhibitor |
Others | Others |
33-BCRP抑制剂是一种乳腺癌耐药蛋白(BCRP)的抑制剂。它使得对米托蒽醌耐药的H460/MX20肺癌细胞对米托蒽醌诱导的细胞死亡更加敏感,无论是单独使用还是与UV辐射联合使用。33-BCRP抑制剂还能够增强表达P-糖蛋白(P-gp,亦称为多药耐药蛋白MDR)的KB-C2表皮癌细胞对秋水仙碱诱导的细胞死亡的敏感性。当使用5 µM浓度时,它能增加米托蒽醌在H460/MX20细胞中的细胞内积累。 | |||
T61351 |
Pixantrone hydrochloride
|
Others | Others |
Pixantrone (BBR 2778 (free base)) hydrochloride is a mitoxantrone analog compound that acts as a topoisomerase II inhibitor and DNA intercalator. It displays anti-tumor activity [1] [2]. | |||
T74737 |
mono-Pal-MTO
|
Others | Others |
Mono-Pal-MTO 是米托蒽醌 (MTO) 与棕榈酸结合的棕榈基脂质,其抗癌活性得以显著提升。当摩尔比1:1时,将mono-Pal-MTO与di-Pal-MTO的纳米颗粒组合使用,可有效递送siRNA至细胞内,进一步增强其抗癌效果。 | |||
T74738 |
di-Pal-MTO
|
Others | Others |
di-Pal-MTO,一种棕榈油基脂质,由抗癌活性分子米托蒽醌(MTO)与棕榈油酸以1:1的摩尔比结合形成。当以纳米颗粒形式将mono-Pal-MTO与di-Pal-MTO联合使用时,能有效递送siRNA至细胞内,并显著增强抗癌活性。 | |||
T70222 |
Ethonafide
|
Others | Others |
Ethonafide is an anthracene-containing derivative of amonafide that belongs to the azonafide series of anticancer agents. The lack of cross-resistance in multidrug-resistant cancer cell lines and the absence of a quinone and hydroquinone moiety make ethonafide a potentially less cardiotoxic replacement for existing anthracene-containing anticancer agents. Ethonafide was cytotoxic against three human prostate cancer cell lines at nanomolar concentrations. Ethonafide was found to be better tolerat... | |||
T62582 |
WEHI-150
|
Others | Others |
WEHI-150是一种米托蒽醌类似物,作为DNA链间交联剂,具有12.5小时的半衰期。该化合物能够在CpG序列上形成共价加合物,对甲基化CpG位点表现出选择性。甲醛激活的WEHI-150能够诱导DNA链间交联,并表现出浓度依赖性的转录阻断作用。此外,WEHI-150还能在新的DNA序列中形成加合物,这不涉及与鸟嘌呤N-2的相互作用。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TN3150 |
6,8-Diprenylnaringenin
6,8-二异戊二烯基柚皮素,Senegalensin,Lonchocarpol A |
BCRP; ABC | Membrane transporter/Ion channel |
6,8-Diprenylnaringenin (Senegalensin) 是来自蛇麻草 Humulus lupulus 的天然产物。 6,8-Diprenylnaringenin 是一种乳腺癌耐药蛋白 (BCRP) 抑制剂,具有一定雌激素作用。 |